openPR Logo
Press release

Braf Kinase Inhibitors Market Detailed In New Research Report 2024 |F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc

08-28-2024 11:07 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Coherent Market Insights

Braf Kinase Inhibitors Market

Braf Kinase Inhibitors Market

The latest market intelligence report published by CMI with the title "Global Braf Kinase Inhibitors Market 2024, Growth Opportunities, and Forecast" provides actionable insights on Pharmaceutical industry. The report provides demand analysis, industry insights, competitive intelligence, and customer database.

The Research report on Braf Kinase Inhibitors Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five Forces Analysis, PESTLE Analysis, Value Chain Analysis, 4 Ps' Analysis, Market Attractiveness Analysis, BPS Analysis, Ecosystem Analysis.

Do you think, if this report could be of your interest? If yes, request Sample Copy of this Report: : - https://www.coherentmarketinsights.com/insight/request-sample/4240

*Note: Sample of the report provides details on the scope and coverage, table of contents, research methodology, and Sample Framework of the report. Actual report of 150+ is available for purchase to all the interested stakeholders.

***key trends***

- Expanded Indications: Clinical trials show promise for Braf inhibitors in treating other cancers like colorectal and NSCLC. This could open major new revenue streams totaling $5B by 2031.

- Personalized Medicine Takes Hold: Biomarker testing and combo therapies are allowing oncologists to precisely match patients to available Braf inhibitors, improving outcomes.

- Asia Pacific Sparks Growth: Regional pharma giants like BeiGene and Incyte partnering with global players to address the large populations and healthcare needs in China and India.

- Biosimilars Rise: The expiry of patent protection for blockbuster drugs like Zelboraf and Tafinlar will drive increased competition and lower costs through 2024.

- Digital Trials Transform R&D: Decentralized and virtual clinical trials enabled by telehealth are accelerating drug development timelines by an average of 6 months.

Want to access more insights? The journey starts from requesting Sample: : - https://www.coherentmarketinsights.com/insight/request-sample/4240

*Note: Sample of the report provides details on the scope and coverage, table of contents, research methodology, and Sample Framework of the report. Actual report of 150+ is available for purchase to all the interested stakeholders.

Detailed Segmentation and Classification of the report (Market Size and Forecast - 2031, Y-o-Y growth rate, and CAGR):

By Drug: Vemurafenib, Dabrafenib, Lifirafenib, Encorafenib.
By Indication: Metastatic Melanoma, Metastatic Lung Cancer, Others.
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

• By Regions and Countries

o North America
o Europe
o Asia-Pacific
o South America
o Middle East & Africa

Following are the players analyzed in the report:

◘ F. Hoffmann-La Roche AG
◘ Novartis International AG
◘ Pfizer Inc.

Get access to the latest Edition of this Market Study (comprising 150+ pages) and Get Up to 25% Discount: : https://www.coherentmarketinsights.com/insight/buy-now/4240

Deep-dive Analysis:

The Report provides deep-dive qualitative and quantitative analysis on Braf Kinase Inhibitors Market for all the regions and countries covered below:

➢ North America (the United States, Canada, and Mexico)
➢ Europe (Germany, France, Italy, United Kingdom, SCANDIVAN, Benelux, Russia, and Rest of Europe)
➢ Asia-Pacific (Japan, South Korea, India, China, Southeast Asia, and Australia)
➢ South America (Brazil, Argentina, and Rest of South America)
➢ Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa, and Rest of the Middle East & Africa)
➢ Each Country is covered in detail, and report provides qualitative and quantitative analysis on Braf Kinase Inhibitors Market on each country.

The research provides answers to the following key questions:

1.What is the estimated growth rate of the market for the forecast period 2024-2031? What will be the market size during the estimated period?
2.What are the key driving forces responsible for shaping the fate of the Braf Kinase Inhibitors market during the forecast period?
3.Who are the major market vendors and what are the winning strategies that have helped them occupy a strong foothold in the Braf Kinase Inhibitors market?
4.What are the prominent market trends influencing the development of the Braf Kinase Inhibitors market across different regions?
5.What are the major threats and challenges likely to act as a barrier in the growth of the Braf Kinase Inhibitors market?
6.What are the major opportunities the market leaders can rely on to gain success and profitability?

Key insights provided by the report that could help you take critical strategic decisions?

• Regional report analysis highlighting the consumption of products/services in a region also shows the factors that influence the market in each region.
• Reports provide opportunities and threats faced by suppliers in the Braf Kinase Inhibitors and tubes industry around the world.
• The report shows regions and sectors with the fastest growth potential.
• A competitive environment that includes market rankings of major companies, along with new product launches, partnerships, business expansions, and acquisitions.
• The report provides an extensive corporate profile consisting of company overviews, company insights, product benchmarks, and SWOT analysis for key market participants.
• This report provides the industry's current and future market outlook on the recent development, growth opportunities, drivers, challenges, and two regional constraints emerging in advanced regions.
• This report provides the industry's current and future market outlook on the recent development, growth opportunities, drivers, challenges, and two regional constraints emerging in advanced regions.

Author of this marketing PR:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

☎ Contact Us:

Mr. Shah
Senior Client Partner - Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Australia: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter

About Us:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Braf Kinase Inhibitors Market Detailed In New Research Report 2024 |F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc here

News-ID: 3637464 • Views:

More Releases from Coherent Market Insights

Current Sensor Market Set to Witness Significant Growth by 2025-2032 - Coherent Market Insights
Current Sensor Market Set to Witness Significant Growth by 2025-2032 - Coherent …
The Current Sensor market is estimated to be valued at USD 3.42 Bn in 2025 and is expected to reach USD 6.75 Bn by 2032, growing at a compound annual growth rate CAGR of 10.2% from 2025 to 2032. ➤ Coherent Market Insights has published an in-depth research report titled "Current Sensor Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032." This study offers a deep dive into the Current
U.S. Bodyguard Service & Security Consulting Market Evolution by 2032 - Disruptive Innovations, Regional Insights, and Growth Opportunities
U.S. Bodyguard Service & Security Consulting Market Evolution by 2032 - Disrupti …
The U.S. Bodyguard Service & Security Consulting market is estimated to be valued at USD 2.57 Bn in 2025 and is expected to reach USD 3.52 Bn by 2032, growing at a compound annual growth rate CAGR of 4.6% from 2025 to 2032. ➤ Coherent Market Insights has published an in-depth research report titled "U.S. Bodyguard Service & Security Consulting Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032." This
Single Cell Sequencing Market Set for Dynamic Boom as Key Players Illumina, BD Biosciences, Pacific Biosciences, Thermo Fisher Scientific
Single Cell Sequencing Market Set for Dynamic Boom as Key Players Illumina, BD B …
The qualitative latest Research report (2025-2032) on the Single Cell Sequencing Market 2025 - 2032 by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves. ➤ Request a Sample
Nuclear Medicine Equipment Market Set for Demonstrate Strong Growth During 2025-2032 with Key Players GE Healthcare, Siemens Healthineers, Philips, and Canon Medical Systems
Nuclear Medicine Equipment Market Set for Demonstrate Strong Growth During 2025- …
The qualitative latest Research report (2025-2032) on the Nuclear Medicine Equipment Market 2025 - 2032 by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves. ➤ Request a Sample

All 5 Releases


More Releases for Braf

BRAF + NSCLC Pipeline Landscape Report 2025: Novel Therapies, Market Outlook, an …
DelveInsight's, "BRAF-mutant Non-Small Cell Lung Cancer (BRAF + NSCLC) Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in BRAF-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Curious about
BRAF Metastatic NSCLC Market to Reach USD 2.56 Billion by 2034
The B-Rapidly Accelerated Fibrosarcoma (BRAF) mutation-positive metastatic non-small cell lung cancer (NSCLC) market is emerging as a critical segment within the oncology therapeutics landscape. NSCLC accounts for nearly 85% of all lung cancer cases globally, and while BRAF mutations occur in only 1-3% of patients, they represent a unique subset with distinct biological and clinical features. Over the next decade, the market is poised for robust growth as targeted therapies,
BRAF-mutant Non-Small Cell Lung Cancer Pipeline: 10+ Companies Advancing Targete …
The treatment landscape for BRAF-mutant Non-Small Cell Lung Cancer (BRAF+ NSCLC), a molecular subtype of NSCLC driven by mutations in the BRAF gene, most commonly the V600E mutation, is rapidly evolving. Traditionally associated with poor prognosis, BRAF+ NSCLC has witnessed significant clinical progress with the development of targeted therapies that inhibit aberrant MAPK pathway signaling. With growing recognition of the heterogeneity and aggressiveness of BRAF-driven tumors, biopharmaceutical companies are increasingly
BRAF Kinase Inhibitors Market Size Opportunities and Challenges for the Future
The global BRAF Kinase Inhibitors Market was valued at approximately USD 289 million and is projected to reach around USD 618 million by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2032 . BRAF Kinase Inhibitors Market Overview The BRAF Kinase Inhibitors Market is experiencing significant growth, driven by the increasing prevalence of cancers associated with BRAF mutations, such as melanoma, colorectal cancer, and non-small cell
BRAF Kinase Inhibitors Market to see Huge Growth by 2029
BRAF Kinase Inhibitors Market is anticipated to grow at a significant CAGR during the forecast period. BRAF is a kinase enzyme that helps control cell growth and signalling. This enzyme can be found in a mutated form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins helps to stop the cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. The
Global BRAF Kinase Inhibitors Market Size, Share and Forecast 2021-2027
The global BRAF kinase inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). BRAF is a kinase enzyme that helps control cell growth and signalling. This enzyme can be found in a mutated form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins helps to stop the cancer cells from growing. Some BRAF kinase inhibitors are used to